REPCF Stock News Replicel Life Sciences Inc (REPCF) 0.5600 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Replicel Life Sciences Inc (REPCF) 0.5600 $REPCF

RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance
Marketwire - Wed Jul 16, 8:00PM CDT
RepliCel Life Sciences Inc. (the "Company" (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has appointed Brooke Hurford, CA as Corporate Secretary and Director, Finance.

RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
Marketwire - Fri Jun 20, 4:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained O&M Partners, LLC to assist in targeting non-deal institutional and independent money managers throughout the United States including financial centres often overlooked by biotech companies. This marketing effort will include a combination of group Town Hall conference calls and follow-up roadshows. With the commencement of three human clinical trials before year-end, management is dedicated to meeting as many non-deal investors as possible. This campaign is an integral part of the company's overall marketing effort focused on the United States.

Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)
PR Newswire - Thu Jun 19, 8:59AM CDT
Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness.

RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement
Marketwire - Wed Jun 18, 1:29AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company" (TSX VENTURE: RP)(OTCQB: REPCF), is pleased to announce it has completed the third and final tranche of its non-brokered financing (the "Financing" announced on March 28, 2014, which consisted of a non-brokered private placement of 866,000 units (each a "Unit" at a price of $0.75 per Unit for gross proceeds of $649,500 (the "Offering" . The total final gross proceeds for the Unit offering were $3,990,125.25. Each Unit consists of one common share of the Company (each, a "Share" and one Share purchase warrant (the "Warrant" , which will entitle the holder to purchase one additional Share for a period of two years from the closing of the private placement at a price of $1.00 per Share during the first year and $1.25 per Share during the second year. This financing was led by Crossover Healthcare Fund, LLC.

RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant
Marketwire - Thu Jun 05, 4:15PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Christina Cameron as its Canadian Investor Relations consultant to create and execute the company's investor relations strategy within Canada.

RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
Marketwire - Tue May 20, 7:05AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP) a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that its RCH-01 licensing partner, Shiseido, celebrated the opening of its new cell-processing facility at the Kobe Biomedical Innovation Cluster (KBIC) located on Port Island, Japan on May 18, 2014. Dignitaries, physicians, partner companies, and government representatives were in attendance at this important event. Shiseido's state-of-the-art facility will focus on the continued research and development, and the commercialization of RepliCel's RCH-01 hair regeneration technology.

RepliCel Reports 2013 Annual Financial Results
Marketwire - Tue Mar 18, 7:04AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today reported financial results for the year ended December 31, 2013.

RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
Marketwire - Thu Feb 27, 7:05AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) announced that its Director of Research and Development, Dr. Hisae Nakamura, and its Chief Medical Officer, Dr. Kevin McElwee, will be presenting at the 13th Congress of the Japanese Society for Regenerative Medicine to be held March 4-6, 2014 in Kyoto, Japan. An oral presentation of Phase 1 clinical data for RCH-01 is scheduled for March 5, 2014 between 3-5 p.m. local time.

RepliCel Retains Ubika Communication for Online Capital Market Exposure
Marketwire - Wed Feb 26, 4:01PM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Ubika Communication, a division of Ubika Corporation, to provide capital market exposure. Ubika offers capital market exposure services via their flagship website portal smallcapower.com (SCP) which is also featured on the Financial Post website. SCP represents a unique way for small cap companies to bridge between the traditional investor relations business model and the online world that is becoming increasingly important for maximizing shareholder value.

Androgenic Alopecia - Pipeline Review, H2 2013
M2 - Fri Feb 07, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/567n76/androgenic) has announced the addition of the "Androgenic Alopecia - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Androgenic Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Androgenic Alopecia. Androgenic Alopecia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Androgenic Alopecia. - A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Androgenic Alopecia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Allergan - Histogen - Hygeia Therapeutics - Kasiak Research - Polichem - R-Tech Ueno - RepliCel Life Sciences - SWITCH Biotech - Samumed For more information visit http://www.researchandmarkets.com/research/567n76/androgenic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.

Eurasian Minerals Announces Royalty Interests on Timok Joint Venture Copper-Gold Properties in Serbia
Marketwire - Tue Feb 04, 6:01AM CST
Eurasian Minerals Inc. (TSX VENTURE: EMX)(NYSE MKT: EMXX) (the "Company" or "EMX" is pleased to announce the acquisition of an uncapped 0.5% net smelter return ("NSR" royalty covering Reservoir Minerals Inc.'s ("Reservoir" or "RMC" share of minerals and metals mined from the "Brestovac" and "Jasikovo East" properties in Serbia. These properties occur in the Timok Magmatic Complex, and are included in the Timok Project joint venture between Reservoir (45%) and Freeport-McMoRan Exploration Corp. ("Freeport" (55%). The Brestovac property hosts porphyry and epithermal copper-gold mineralization at the Cukaru Peki discovery, and the Jasikovo East property occurs to the north in the Timok copper-gold belt. Reservoir recently announced an initial NI 43-101 compliant resource estimate for the Cukaru Peki deposit. EMX congratulates Reservoir and Freeport on achieving this important milestone, as well as their continuing Timok Project exploration successes.

RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
Marketwire - Mon Jan 13, 7:02AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) today announced that it has been granted a patent by Japan's Ministry of International Trade and Industry for hair follicle mesenchymal stem cells and their use thereof. These cells are used in RepliCel's RCH-01 treatment for androgenetic alopecia, also known as pattern hair loss. With the issuance of this patent, RepliCel now has patents issued in Japan, the United States, Australia and the European Union protecting its technology with other jurisdictions still pending.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 20

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
LONGi's Four Paths to Global Green Development

Updated Category News Views 79

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Venezuela's Political Shift and Its Impact on Global Oil Markets

Updated Category News Views 122

Venezuela's Dramatic Political Changes and Market Reactions Recent events in Venezuela have created quite a stir. With the U.S. capturing Nicolás Maduro, the country's president, and extraditing him for trial, one might expect a major upheaval in financial and commodity markets. Surprisingly, the markets seem largely unaffected by this significant geopolitical shift....

Continue Reading
Paradigm Health Pushes Innovative FDA Trial Initiative

Updated Category News Views 27

The FDA's Real-Time Game Changer Just up and submitting their convincing response to the FDA, Paradigm Health's grabbing headlines with a trailblazing initiative right out of Columbus, Ohio. The FDA's Real-Time Clinical Trials (RTCT) proof-of-concept has been a field where Paradigm wields its AI-driven wand, proposing a plan that promises to streamline clinical trial...

Continue Reading
DSV A/S Launches Major Share Buyback Program Announcement

Updated Category News Views 74

DSV A/S Launches Major Share Buyback Program Company Announcement No. 1130 In a strategic effort to boost shareholder value, DSV A/S has launched a share buyback program. This initiative officially began on July 24, 2024, and is expected to wrap up on October 22, 2024. The company plans to repurchase its own shares totaling up to DKK 1,500 million, which corresponds to a...

Continue Reading
Insights into the Growth of the Global Fondant Market Trends

Updated Category News Views 230

Exploring the Global Fondant Market Trends The fondant market is rapidly evolving, driven by a surge in consumer preferences for aesthetically pleasing dessert options. Recent research identifies that the fondant market size, valued at approximately USD 520.45 Million, is anticipated to reach around USD 898.79 Million by 2034, reflecting a robust compound annual growth...

Continue Reading
Innocan Pharma's Strategic Move: Private Placement Details

Updated Category News Views 110

Innocan Pharma's Exciting Private Placement Initiative Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) has announced a significant financial move by planning a non-brokered private placement. This initiative aims to issue up to 3,500,000 units, priced at C$0.20 each, bringing in gross proceeds of up to C$700,000. This offering is designed to expedite the...

Continue Reading